IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Pharma, SAI MedPartners

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s br...

About PodLP

PodLP is the leading podcast app for feature phones. With 10M+ installs in nearly every country, PodLP is available for KaiOS on the KaiStore and JioStore, as well as Cloud Phone and Android. If you're interested in promoting "IDEA Collider: Innovation & Asymmetric Learning in Pharma" on PodLP, contact sales@podlp.com.

Screenshots are mockup renders of PodLP for KaiOS. Actual design may vary based on platform, operating system, and app version.

IDEA Collider: Innovation & Asymmetric Learning in Pharma

Episodes (67)

Wed May 13th Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping
Apr 27th Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
Apr 9th Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy

IDEA Collider: Innovation & Asymmetric Learning in Pharma

May 13, 2026
35 minutes
32 MB

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors. While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach. Anocca is building a fully integrated platform that comb...

IDEA Collider: Innovation & Asymmetric Learning in Pharma

Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping

IDEA Pharma, SAI MedPartners

00:00 -34:53